Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome

Exclusion Criteria

• •1. Pregnant/lactating women or planning on becoming pregnant during the study
• •2. Known hypersensitivity to vitamin D or its components.
• •3. Pre-existing renal stone disease, chronic renal disease with glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m2 or renal dialysis.
• •4. Liver failure or chronic liver disease with liver enzymes \> 2 fold upper limit of normal (ULN).
• •5. History of parathyroid disease or granulomatous disease (TBC and sarcoidosis)
• •6. History of malabsorption syndrome or any medical condition that might interfere with vitamin D absorption.
• •7. History of small intestine resection.
• •8. History of other malignancy within the last 5 years except for carcinoma in situ of the cervix or basal cell carcinoma or squamous cell carcinoma of the skin or in situ malignant melanoma.
• •9. Chronic alcohol abuse.
• •10. Medical or logistic problems likely to preclude completion of the study.
• •11. Taking medication that predisposes to hypercalcemia (digoxin, lithium, thiazide diuretics) or taking medication that would affect metabolism of vitamin D (anticonvulsants, corticosteroids, H2-receptor antagonists)
• •12. Intake of vitamin D supplements within 6 months prior to entry of the study.